| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Zeliha Hekimsoy, Bilgin Ozmen, Sadik Uluso. Homocysteine levels in acromegaly patients. Neuro endocrinology letters. vol 26. issue 6. 2006-06-02. PMID:16380700. |
acromegaly patients with high gh levels after an ogtt have much higher levels of homocysteine than patients with lower gh levels. |
2006-06-02 |
2023-08-12 |
Not clear |
| Weifeng Ruan, Fabian Fahlbusch, David R Clemmons, Marie E Monaco, Paul D Walden, Antonio P Silva, Herbert A Schmid, David L Kleinber. SOM230 inhibits insulin-like growth factor-I action in mammary gland development by pituitary independent mechanism: mediated through somatostatin subtype receptor 3? Molecular endocrinology (Baltimore, Md.). vol 20. issue 2. 2006-05-18. PMID:16223973. |
somatostatin analogs (sas) treat acromegaly by lowering pituitary gh secretion, which, in turn, lowers systemic igf-i. |
2006-05-18 |
2023-08-12 |
rat |
| Vicente E Climent, Antonio Picó, Francisco Sogorb, Silvia Aznar, Gregory Y H Lip, Francisco Marí. Growth hormone therapy and the heart. The American journal of cardiology. vol 97. issue 7. 2006-05-04. PMID:16563925. |
gh therapy is recommended treatment in adult patients with gh deficiency, but in acromegaly, in which there is excess gh, the main cause of mortality is cardiovascular disease. |
2006-05-04 |
2023-08-12 |
human |
| Orhan Sen, M Eda Ertorer, M Volkan Aydin, Bulent Erdogan, Nur Altinors, Suzan Zorludemir, Nilgun Guvene. Silent pituitary macroadenoma co-secreting growth hormone and thyroid stimulating hormone. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia. vol 12. issue 3. 2006-04-26. PMID:15851094. |
we report a case of a silent macroadenoma with both growth hormone (gh) and thyroid stimulating hormone (tsh) staining and secretion but with no clinical manifestations, in particular, the absence of features of acromegaly or hyperthyroidism. |
2006-04-26 |
2023-08-12 |
Not clear |
| Annamaria Colao, Rosario Pivonello, Renata S Auriemma, Maria Cristina De Martino, Martin Bidlingmaier, Francesco Briganti, Fabio Tortora, Pia Burman, Ione A Kourides, Christian J Strasburger, Gaetano Lombard. Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance. European journal of endocrinology. vol 154. issue 3. 2006-04-20. PMID:16498061. |
efficacy of 12-month treatment with the gh receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on igf-i levels, tumor mass, hypertension and glucose tolerance. |
2006-04-20 |
2023-08-12 |
Not clear |
| Ferdinand Roelfsema, Nienke R Biermasz, Johannes A Romijn, Alberto M Pereir. Treatment strategies for acromegaly. Expert opinion on emerging drugs. vol 10. issue 4. 2006-04-14. PMID:16262568. |
acromegaly is a chronic debilitating disorder caused by a growth hormone (gh)-producing pituitary adenoma. |
2006-04-14 |
2023-08-12 |
Not clear |
| Carmen Z Michaylira, Nicole M Ramocki, James G Simmons, C Kirby Tanner, Kirk K McNaughton, John T Woosley, Christopher J Greenhalgh, P Kay Lun. Haplotype insufficiency for suppressor of cytokine signaling-2 enhances intestinal growth and promotes polyp formation in growth hormone-transgenic mice. Endocrinology. vol 147. issue 4. 2006-04-14. PMID:16410303. |
excessive trophic effects of gh or igf-i may contribute to neoplastic growth or increased colorectal cancer risk in acromegaly. |
2006-04-14 |
2023-08-12 |
mouse |
| Carmen Z Michaylira, Nicole M Ramocki, James G Simmons, C Kirby Tanner, Kirk K McNaughton, John T Woosley, Christopher J Greenhalgh, P Kay Lun. Haplotype insufficiency for suppressor of cytokine signaling-2 enhances intestinal growth and promotes polyp formation in growth hormone-transgenic mice. Endocrinology. vol 147. issue 4. 2006-04-14. PMID:16410303. |
small variations in socs2 expression levels may significantly influence the outcome of therapeutic gh or acromegaly in intestine. |
2006-04-14 |
2023-08-12 |
mouse |
| M Gola, S Bonadonna, G Mazziotti, G Amato, A Giustin. Resistance to somatostatin analogs in acromegaly: an evolving concept? Journal of endocrinological investigation. vol 29. issue 1. 2006-04-14. PMID:16553040. |
the aim of acromegaly treatment is to control the disease by suppressing gh hyperactivity and reducing the size or impeding the growth of the pituitary gh secreting mass. |
2006-04-14 |
2023-08-12 |
Not clear |
| Helene Markkanen, Tuula Pekkarinen, Matti J Välimäki, Henrik Alfthan, Ritva Kauppinen-Mäkelin, Timo Sane, Ulf-Håkan Stenma. Effect of sex and assay method on serum concentrations of growth hormone in patients with acromegaly and in healthy controls. Clinical chemistry. vol 52. issue 3. 2006-04-13. PMID:16439607. |
diagnosis and follow-up of acromegaly is based on measurements of serum growth hormone (gh) concentrations during an oral glucose tolerance test (ogtt). |
2006-04-13 |
2023-08-12 |
Not clear |
| H Biering, B Saller, J Bauditz, M Pirlich, B Rudolph, A Johne, M Buchfelder, K Mann, M Droste, I Schreiber, H Lochs, C J Strasburge. Elevated transaminases during medical treatment of acromegaly: a review of the German pegvisomant surveillance experience and a report of a patient with histologically proven chronic mild active hepatitis. European journal of endocrinology. vol 154. issue 2. 2006-04-04. PMID:16452533. |
the new gh receptor antagonist pegvisomant is the most effective medical therapy to normalize igf-i levels in patients with acromegaly. |
2006-04-04 |
2023-08-12 |
Not clear |
| Ana Pokrajac, Andrew G Claridge, S K Abdul Shakoor, Peter J Traine. The octreotide test dose is not a reliable predictor of the subsequent response to somatostatin analogue therapy in patients with acromegaly. European journal of endocrinology. vol 154. issue 2. 2006-04-04. PMID:16452540. |
we have analysed the value of the gh response to a td in predicting the efficacy of subsequent sat in 47 patients with acromegaly (25 male, median age 51 years, range 20-82). |
2006-04-04 |
2023-08-12 |
Not clear |
| Cornelia Metzner, Senad Hadziselimovic, Ingo Grafe, Peter Nawroth, Christian Kasper. [Therapeutic management of acromegaly]. Medizinische Klinik (Munich, Germany : 1983). vol 101. issue 1. 2006-03-20. PMID:16418810. |
only 60% of the patients with acromegaly are biochemically cured (growth hormone [gh] nadir < 1.0 microg/l after an oral glucose load, normalized age- and gender-matched insulin-like growth factor-1 [igf-1] levels) after transsphenoidal surgery of the pituitary gland. |
2006-03-20 |
2023-08-12 |
Not clear |
| Katharina M Main, Astrid Sehested, Ulla Feldt-Rasmusse. Pegvisomant treatment in a 4-year-old girl with neurofibromatosis type 1. Hormone research. vol 65. issue 1. 2006-03-02. PMID:16269873. |
recently, a gh receptor antagonist, pegvisomant, was introduced for the treatment of adults with acromegaly. |
2006-03-02 |
2023-08-12 |
Not clear |
| Marek Bolanowski, Jacek Daroszewski, Marek Medraś, Beata Zadrozna-Sliwk. Bone mineral density and turnover in patients with acromegaly in relation to sex, disease activity, and gonadal function. Journal of bone and mineral metabolism. vol 24. issue 1. 2006-03-02. PMID:16369902. |
acromegaly is a rare disease caused by growth hormone (gh) hypersecretion. |
2006-03-02 |
2023-08-12 |
human |
| Marek Bolanowski, Jacek Daroszewski, Marek Medraś, Beata Zadrozna-Sliwk. Bone mineral density and turnover in patients with acromegaly in relation to sex, disease activity, and gonadal function. Journal of bone and mineral metabolism. vol 24. issue 1. 2006-03-02. PMID:16369902. |
an anabolic effect of gh during active acromegaly was present in the proximal femur only in men. |
2006-03-02 |
2023-08-12 |
human |
| Fausto Bogazzi, Dania Russo, Maria Teresa Locci, Barbara Chifenti, Federica Ultimieri, Francesco Raggi, Chiara Cosci, Chiara Sardella, Aurelio Costa, Maurizio Gasperi, Luigi Bartalena, Enio Martin. Apoptosis is reduced in the colonic mucosa of patients with acromegaly. Clinical endocrinology. vol 63. issue 6. 2006-02-28. PMID:16343104. |
gh and igf-1 decrease apoptosis in several cell lines including human colonic adenocarcinoma, but it is unknown whether epithelial cells of colonic mucosa of patients with acromegaly have reduced apoptosis. |
2006-02-28 |
2023-08-12 |
human |
| A Colao, R Pivonello, R Scarpa, G Vallone, C Ruosi, G Lombard. The acromegalic arthropathy. Journal of endocrinological investigation. vol 28. issue 8 Suppl. 2006-02-03. PMID:16323826. |
since the initial definition of acromegaly over 100 yr ago, extraordinary efforts have been made to control gh levels and the pituitary tumor. |
2006-02-03 |
2023-08-12 |
Not clear |
| Angela N Paisley, William M Drak. Treatment of pituitary tumors: pegvisomant. Endocrine. vol 28. issue 1. 2006-01-24. PMID:16311417. |
the drug is capable of normalizing serum igf-i concentrations (the chief mediator of disease activity in acromegaly) in 97% of patients, and therapy is associated with significant improvements in the symptoms and signs of gh excess. |
2006-01-24 |
2023-08-12 |
Not clear |
| Shereen Ezza. Pharmacological options in the treatment of acromegaly. Current opinion in investigational drugs (London, England : 2000). vol 6. issue 10. 2006-01-06. PMID:16259223. |
secondly, the availability of highly specific and selective pharmacological agents to lower gh and/or igf-i levels has greatly facilitated a more aggressive approach to the treatment of patients with persistently active acromegaly. |
2006-01-06 |
2023-08-12 |
Not clear |